Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The prognosis of adult patients with recurrent malignant embryonal brain tumors remains poor due to the lack of effective and validated treatment. A metronomic and antiangiogenic chemotherapy regimen called MEMMAT was developed in children, with promising results. Additional data on feasibility, tolerance, and efficacy in adults are necessary.
Methods: This retrospective observational case series included adult patients with relapsing medulloblastoma (MB) or pineoblastoma (PB) treated with MEMMAT-adapted protocol. Treatment consisted of daily oral thalidomide, fenofibrate, and celecoxib, and alternating 21-day cycles of metronomic etoposide and cyclophosphamide associated with bevacizumab and personalized intraventricular chemotherapy.
Results: Four SHH-activated MB and 2 PB were included. Median duration of treatment was 12 months (range 3-21). Significant partial response occurred in 2/4 MB patients and 2/2 PB. The best responses were observed on leptomeningeal lesions. Main grade 3-4 toxicity was neutropenia in all patients (no febrile neutropenia) and lymphopenia in all but one (2 opportunistic infections). Dose adjustments in chemotherapy and thalidomide for hematotoxicity were necessary in all patients within the first 3 months. Cumulative neurotoxicity from thalidomide affected the 4 patients with prolonged treatment (1 grade 3, 3 grade 2). Rechallenge was tried in PB patients and successful (duration: 9 months).
Conclusions: MEMMAT is feasible in adult patients and can lead to a significant and sustained response in recurrent malignant embryonal brain tumors. Hematotoxicity is progressive and manageable. The withdrawal of thalidomide and starting dose adjustments on chemotherapy might be discussed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199352 | PMC |
| http://dx.doi.org/10.1093/noajnl/vdaf071 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Randomized trial of activated vitamin D for acute kidney injury prevention in critically ill patients.
JCI Insight
September 2025
Division of Nephrology, Boston University Chobanian & Avedisian School of Medicine, Boston, United States of America.
Background: Active vitamin D metabolites, including 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D), have potent immunomodulatory effects that attenuate acute kidney injury (AKI) in animal models.
Methods: We conducted a phase 2, randomized, double-blind, multiple-dose, 3-arm clinical trial comparing oral calcifediol (25D), calcitriol (1,25D), and placebo among 150 critically ill adult patients at high-risk of moderate-to-severe AKI. The primary endpoint was a hierarchical composite of death, kidney replacement therapy (KRT), and kidney injury (baseline-adjusted mean change in serum creatinine), each assessed within 7 days following enrollment using a rank-based procedure.
Recessive TMEM167A variants cause neonatal diabetes, microcephaly and epilepsy syndrome.
J Clin Invest
September 2025
Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom.
Understanding the genetic causes of diseases affecting pancreatic β cells and neurons can give insights into pathways essential for both cell types. Microcephaly, epilepsy and diabetes syndrome (MEDS) is a congenital disorder with two known aetiological genes, IER3IP1 and YIPF5. Both genes encode proteins involved in endoplasmic reticulum (ER) to Golgi trafficking.
View Article and Find Full Text PDFDaylight Savings Time and Acute Myocardial Infarction.
JAMA Netw Open
September 2025
Division of Cardiology, Duke University Hospital, Durham, North Carolina.
Importance: Previous data suggest that the time changes associated with daylight savings time (DST) may be associated with an increased incidence of acute myocardial infarction (AMI).
Objective: To determine whether the incidence of patients presenting with AMI is greater during the weeks during or after DST and compare the in-hospital clinical events between the week before DST and after DST.
Design, Setting, And Participants: This cross-sectional study examined patients enrolled in the Chest Pain MI Registry from 2013 to 2022.
Bariatric Surgery and Incident Development of Obesity-Related Comorbidities.
JAMA Netw Open
September 2025
Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Importance: As obesity rates rise in the US, managing associated metabolic comorbidities presents a growing burden to the health care system. While bariatric surgery has shown promise in mitigating established metabolic conditions, no large studies have quantified the risk of developing major obesity-related comorbidities after bariatric surgery.
Objective: To identify common metabolic phenotypes for patients eligible for bariatric surgery and to estimate crude and adjusted incidence rates of additional metabolic comorbidities associated with bariatric surgery compared with weight management program (WMP) alone.
Broad-Spectrum Antibiotic Use at the End of Life in Patients With Advanced Cancer.
JAMA Netw Open
September 2025
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.
Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.
Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021.